Fidelity Investments
RCUS icon

Fidelity Investments’s Arcus Biosciences RCUS Stock Holding History

Fidelity Investments’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$125M Buy
4,049,757
+2,884,505
+248% +$71.3M 0.01% 1145
2026
Q1 		$25.2M Buy
1,165,252
+30,074
+3% +$649K ﹤0.01% 1698
2025
Q4 		$27.1M Sell
1,135,178
-1,160,843
-51% -$23.7M ﹤0.01% 1669
2025
Q3 		$31.2M Sell
2,296,021
-277,273
-11% -$2.88M ﹤0.01% 1614
2025
Q2 		$20.9M Sell
2,573,294
-1,883,552
-42% -$16.1M ﹤0.01% 1681
2025
Q1 		$35M Buy
4,456,846
+404,325
+10% +$4.69M ﹤0.01% 1494
2024
Q4 		$60.3M Sell
4,052,521
-415,036
-9% -$6.78M ﹤0.01% 1313
2024
Q3 		$68.3M Buy
4,467,557
+286,766
+7% +$4.52M ﹤0.01% 1243
2024
Q2 		$63.7M Sell
4,180,791
-598,478
-13% -$9.66M ﹤0.01% 1220
2024
Q1 		$90.2M Buy
4,779,269
+50,487
+1% +$873K 0.01% 1100
2023
Q4 		$90.3M Sell
4,728,782
-51,270
-1% -$819K 0.01% 1051
2023
Q3 		$85.8M Buy
4,780,052
+222,280
+5% +$4.47M 0.01% 1045
2023
Q2 		$92.6M Buy
4,557,772
+1,247,936
+38% +$23.8M 0.01% 1027
2023
Q1 		$60.4M Sell
3,309,836
-5,976
-0.2% -$114K 0.01% 1182
2022
Q4 		$68.6M Sell
3,315,812
-39,436
-1% -$1.09M 0.01% 1119
2022
Q3 		$87.8M Buy
3,355,248
+34,092
+1% +$902K 0.01% 1003
2022
Q2 		$84.2M Buy
3,321,156
+642
+0% +$15.7K 0.01% 1034
2022
Q1 		$105M Buy
3,320,514
+127,118
+4% +$4.26M 0.01% 1047
2021
Q4 		$129M Buy
3,193,396
+102,231
+3% +$3.97M 0.01% 990
2021
Q3 		$108M Hold
3,091,165
– – 0.01% 1071
2021
Q2 		$84.9M Buy
3,091,165
+857,505
+38% +$24.5M 0.01% 1192
2021
Q1 		$62.7M Hold
2,233,660
– – 0.01% 1288
2020
Q4 		$58M Sell
2,233,660
-117,282
-5% -$2.84M 0.01% 1265
2020
Q3 		$40.3M Sell
2,350,942
-354,633
-13% -$7.92M ﹤0.01% 1277
2020
Q2 		$66.9M Buy
2,705,575
+2,625,945
+3,298% +$70.9M 0.01% 1049
2020
Q1 		$1.1M Buy
+79,630
New +$990K ﹤0.01% 2312
2019
Q3 		– Sell
-60
Closed – – 4161
2019
Q2 		$0 Buy
+60
New +$601 ﹤0.01% 4101

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments's RCUS Position: Q2 2026 in Review

Fidelity Investments increased its Arcus Biosciences (RCUS) stake by 248% in Q2 2026, buying an estimated $71.3M and bringing the position to 4,049,757 shares worth $125M. The position accounts for 0.01% of the portfolio, ranked #1145.

Fidelity Investments first reported a position in RCUS in Q2 2019 and has held it in 27 quarters since. The position peaked at $129M in Q4 2021. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Fidelity Investments held 4,049,757 shares of Arcus Biosciences worth $125M as of Q2 2026.
  • Fidelity Investments bought 2,884,505 Arcus Biosciences shares in Q2 2026, an estimated $71.3M.
  • Arcus Biosciences made up 0.01% of Fidelity Investments's portfolio in Q2 2026, its #1145 holding.
  • Fidelity Investments first reported a position in Arcus Biosciences in Q2 2019 and has held it in 27 quarters since.
  • Fidelity Investments's Arcus Biosciences position peaked at $129M in Q4 2021.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.